Koichiro Kinugawa, MD


Chairman and Professor of Cardiovascular Medicine and Nephrology

University / Hospital Affiliation

University of Toyama


Prof. Koichiro Kinugawa graduated University of Tokyo in 1988, and was trained in affiliated hospitals and studied abroad in UC San Francisco and UCHSC in Denver until 2002. After coming back to Japan, he started his faulty career as an assistant professor in University of Tokyo, was promoted as an associated professor in 2010, and as a project professor in advanced heart failure division in 2013. He moved to University of Toyama as a chairman and full professor of cardiovascular medicine and nephrology department in 2015. He is now a vice president of University hospital as well. He specializes heart failure especially in mechanical circulatory device and transplantation. He served as a board of directors in Japanese circulation Society, Japanese Heart Failure Society, Japanese Society for Heart Transplantation, Council for Clinical Use of Ventricular Assist Device Related Academic Societies, and other many academic societies. He also worked as an associated editor in Journal of Cardiac Failure and Journal of Cardiology.

Manuscripts & Publications

JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure

In March 2018, the Japanese Circulation Society (JCS)/Japanese Heart Failure Society (JHFS) jointly published the 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure. In this revised edition, a research group comprised of members recommended by 11 academic societies, including the JCS, JHFS, Japanese Association for Thoracic Surgery, Japanese Society of Hypertension, Japanese Society of Echocardiography, Japanese Society for Cardiovascular Surgery, Japanese College of Cardiology, Japanese Association of Cardiac Rehabilitation, Japan Society of Ultrasonics in Medicine, Japan Diabetes Society, and Japanese Heart Rhythm Society (JHRS), was organized.

Natriuretic peptides: role in the diagnosis and management of heart failure: a scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society

Natriuretic peptides, brain (B-type) natriuretic peptide (BNP) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) are globally and most often used for the diagnosis of heart failure (HF). In addition, they can have an important complementary role in the risk stratification of its prognosis. Since the development of angiotensin receptor–neprilysin inhibitors (ARNIs), the use of natriuretic peptides as therapeutic agents has grown in importance.

Interventional heart failure therapy: A new concept fighting against heart failure

Heart failure is a progressive disease that is associated with repeated exacerbations and hospitalizations. The rapid increase in the number of heart failure patients is a global health problem known as the ‘heart failure pandemic’. To control the pandemic, multifaceted approaches are essential, ranging from prevention of onset to long-term disease management.